India's health biotech sector at a crossroads

被引：58

作者：

Frew, Sarah E.

Rezaie, Rahim

Sammut, Stephen M.

Ray, Monali

Daar, Abdallah S.

Singer, Peter A.

机构：

[1] Univ Toronto, McLaughlin Rotman Ctr Global Hlth, Program Life Sci Eth & Policy,MaRS Ctr, Univ Hlth Network,McLaughlin Ctr Mol Med, Toronto, ON M5G 1L7, Canada

[2] Burrill & Co, San Francisco, CA 94111 USA

[3] Univ Penn, Wharton Hlth Care Syst, Philadelphia, PA 19104 USA

来源：

NATURE BIOTECHNOLOGY | 2007年 / 25卷 / 04期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1038/nbt0407-403

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

India's home- grown biotech companies must strike a balance between domestic and international markets.

引用

页码：403 / 417

页数：15

共 16 条

[1]

BLEED D, 2006, GLOBAL TUBERCULOSIS

[2]

De Rond M., 2003, STRATEGIC ALLIANCES

[3]

*DEP BIOT GOV IND, 2006, BIOSP ABLE BIOSP ABL

[4] Bioscience in India: Times are changing [J].

Dhawan, J ;

Gokhale, RS ;

Verma, IM .

CELL, 2005, 123 (05) :743-745

[5] Biotech boom [J].

Jayaraman, KS .

NATURE, 2005, 436 (7050) :480-483

[6]

*JOINT NAT NAT PRO, 2005, AS FACT SHEET UNAIDS

[7]

*KAL INF, 2005, BIOG PHARM FUT EXP B

[8]

KUMAR NK, 2001, NAT BIOTECHNOL S, V22, pDC31

[9] Coming home [J].

Mayor, S .

NATURE, 2005, 436 (7050) :488-489

[10]

Palnitkar U., 2005, J COMMER BIOTECHNOL, V11, P146, DOI [10.1057/palgrave.jcb.3040112, DOI 10.1057/PALGRAVE.JCB.3040112]

← 1 2 →